The goal of this clinical trial is to study whether the use of our blood culture prediction tool is non-inferior to current practice and if it can improve certain outcomes in all adult patients presenting to the emergency department with a clinical indication for a blood culture analysis (according to the treating physician). The primary endpoint is 30-day mortality. Key secondary outcomes are:
* hospital admission rates * in-hospital mortality * hospital length-of-stay. In the intervention group, the physician will follow the advice of our blood culture prediction tool.
In the comparison group all patients will undergo a blood culture analysis.
Age >= 18 years
Have a clinical indication for a blood culture analysis (according to the treating physician)
Have sufficient data recorded (laboratory results and vital sign measurements) for a prediction to be made (at least 20% of the needed parameters)
Central Venous Line (CVL) or Peripherally Inserted Central Catheter (PICC) in situ
Neutrophil count < 0.5 * 109/L
Candidemia or S. aureus bacteraemia in the past 3 months.
Most likely diagnosis of endocarditis/spondylodiscitis/infected prosthetic material
Parallel
Blood culture prediction tool
DeviceMachine learning based predicition tool
30-day mortality
hospital admission rates
in-hospital mortality
hospital length-of-stay
30-day readmission rates
Length of stay in the ED in hours
Percentage of blood cultures avoided in the intervention group
90 day mortality
Click on the lead sponsor to view all of their trials.
